Clinical Trial Update: Anlotinib and TQB2450 in Advanced Hepatocellular Carcinoma After Failure of Prior Immune Checkpoint Inhibitors [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating anlotinib in combination with TQB2450 for advanced hepatocellular carcinoma after prior immune checkpoint inhibitor failure.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Anlotinib (anlotinib)
• TQB2450

Snippet

Sponsor: Shanghai Zhongshan Hospital | Conditions: Hepatocellular Carcinoma | Phase 2 | Status: UNKNOWN